isepamicin

isepamicin

an antibiotic derived from gentamicin and with similar activity.
References in periodicals archive ?
The following antibiotic susceptibilities were reported: [beta]-lactams (ticarcillin, ticarcillin/clavulanate, ceftazidime, cefepime, and cefpirome); aminoglycosides (amikacin, gentamicin, isepamicin, netilmicin, and tobramycin); fluoroquinolones (ciprofloxacin, levofloxacin, and pefloxacin); carbapenems (imipenem and meropenem); extended-spectrum [beta]-lactams (aztreonam, piperacillin, andpiperacillin/tazobactam); sulfonamides (trimethoprim/sulfamethoxazole); tetracyclines (minocycline), and polymyxins (colistin).
The fluoroquinolone-resistant strains in recurrent infection showed high cross-resistance to aminoglycosides (amikacin, gentamicin, netilmicin, isepamicin, and tobramycin), [beta]-lactams (ticarcillin, ticarcillin/clavulanate, cefpirome, ceftazidime, and cefepime), and extended-spectrum [beta]-lactams (aztreonam) (p < 0.
The aim of this study was to evaluate the susceptibility of clinically isolated Enterobacteriaceae to isepamicin and amikacin using disc diffusion method.
sup][7],[8],[9] In Taiwan, a recent research has reported an increase in the resistance rates of Gram-negative pathogens to isepamicin that was introduced more than 10 years ago.
However, the in vitro data of susceptibility testing of isepamicin using the antimicrobial discs are unavailable.
Antimicrobial susceptibilities to gentamicin, amikacin, and isepamicin were assessed using disc diffusion method and interpreted according to the manufacturer's instructions and the guidelines of the Clinical and Laboratory Standards Institute (CLSI), [sup][11] respectively.
All isolates were tested in parallel for susceptibility to isepamicin and amikacin.
amikacin, netilmicin, arbekacin, isepamicin and dibekacin, are also in use as chemotherapeutic agents, in particular against resistant bacteria.
APH(3')-VI confers resistance to amikacin and isepamicin.
Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia.
The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
Comparative inactivation of isepamicin, amikacin, and gentamicin by nine beta-lactam and two beta-lactamase inhibitors, cilastatin and heparin.